GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro have helped millions of Americans lose weight and better ...

The tech company estimates that its investment will create 100,000 jobs focused on AI and emerging technologies. Canal+'s shares fell on the London Stock Exchange and Havas's stock rose on Euronext ...

Ratings for the No. 2 and No. 3 cable news networks have plummeted since Donald Trump's victory, while Fox News remains the leader. The president-elect sued after George Stephanopoulos inaccurately ...

The global obesity epidemic represents one of the most pressing public health challenges of our time. With nearly ...

Robert F. Kennedy Jr., a prominent critic of the pharmaceutical industry, discussed his views regarding GLP-1 weight loss drugs in a televised broadcast.

Eli Lilly (LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug ...

The Australian market is poised for a positive start with the ASX 200 expected to open slightly higher, buoyed by China's commitment to proactive fiscal policies which has positively impacted ...

People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly-sponsored study, compared with a 13.7% loss for Wegovy patients, Lilly said Wednesday.

Eli Lilly, opens new tab said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's (NOVOb.CO), opens new tab Wegovy in the first ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. Photo by Pixabay/Pexels Zepbound, the new GLP-1 ...

Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical ...

Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical trial results. Zepound manufacturer Eli Lilly released results from ...